company background image
M12 logo

M1 Kliniken XTRA:M12 Stock Report

Last Price

€13.80

Market Cap

€252.7m

7D

-1.1%

1Y

99.4%

Updated

15 Apr, 2024

Data

Company Financials +

M12 Stock Overview

M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, and Australia.

M12 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health5/6
Dividends0/6

M1 Kliniken AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for M1 Kliniken
Historical stock prices
Current Share Price€13.80
52 Week High€14.95
52 Week Low€6.90
Beta1.14
1 Month Change6.98%
3 Month Change28.37%
1 Year Change99.42%
3 Year Change17.95%
5 Year Change-1.78%
Change since IPO176.06%

Recent News & Updates

At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?

Mar 07
At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?

Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge

Feb 18
Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge

Recent updates

At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?

Mar 07
At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?

Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge

Feb 18
Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge

Is M1 Kliniken AG (ETR:M12) Trading At A 46% Discount?

Feb 17
Is M1 Kliniken AG (ETR:M12) Trading At A 46% Discount?

An Intrinsic Calculation For M1 Kliniken AG (ETR:M12) Suggests It's 27% Undervalued

Sep 01
An Intrinsic Calculation For M1 Kliniken AG (ETR:M12) Suggests It's 27% Undervalued

Should You Think About Buying M1 Kliniken AG (ETR:M12) Now?

Jun 01
Should You Think About Buying M1 Kliniken AG (ETR:M12) Now?

The Returns On Capital At M1 Kliniken (ETR:M12) Don't Inspire Confidence

Mar 25
The Returns On Capital At M1 Kliniken (ETR:M12) Don't Inspire Confidence

Investors Could Be Concerned With M1 Kliniken's (ETR:M12) Returns On Capital

Dec 17
Investors Could Be Concerned With M1 Kliniken's (ETR:M12) Returns On Capital

Is Now The Time To Look At Buying M1 Kliniken AG (ETR:M12)?

Nov 02
Is Now The Time To Look At Buying M1 Kliniken AG (ETR:M12)?

Time To Worry? Analysts Are Downgrading Their M1 Kliniken AG (ETR:M12) Outlook

May 26
Time To Worry? Analysts Are Downgrading Their M1 Kliniken AG (ETR:M12) Outlook

Analysts Have Lowered Expectations For M1 Kliniken AG (ETR:M12) After Its Latest Results

May 25
Analysts Have Lowered Expectations For M1 Kliniken AG (ETR:M12) After Its Latest Results

Here's What's Concerning About M1 Kliniken's (ETR:M12) Returns On Capital

Dec 06
Here's What's Concerning About M1 Kliniken's (ETR:M12) Returns On Capital

There Are Reasons To Feel Uneasy About M1 Kliniken's (ETR:M12) Returns On Capital

May 22
There Are Reasons To Feel Uneasy About M1 Kliniken's (ETR:M12) Returns On Capital

Here's What M1 Kliniken AG's (ETR:M12) Shareholder Ownership Structure Looks Like

Mar 19
Here's What M1 Kliniken AG's (ETR:M12) Shareholder Ownership Structure Looks Like

We're Watching These Trends At M1 Kliniken (ETR:M12)

Feb 21
We're Watching These Trends At M1 Kliniken (ETR:M12)

M1 Kliniken (ETR:M12) Has Gifted Shareholders With A Fantastic 106% Total Return On Their Investment

Feb 03
M1 Kliniken (ETR:M12) Has Gifted Shareholders With A Fantastic 106% Total Return On Their Investment

Are Dividend Investors Getting More Than They Bargained For With M1 Kliniken AG's (ETR:M12) Dividend?

Jan 16
Are Dividend Investors Getting More Than They Bargained For With M1 Kliniken AG's (ETR:M12) Dividend?

M1 Kliniken AG's (ETR:M12) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Dec 29
M1 Kliniken AG's (ETR:M12) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Here's Why We Don't Think M1 Kliniken's (ETR:M12) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 14
Here's Why We Don't Think M1 Kliniken's (ETR:M12) Statutory Earnings Reflect Its Underlying Earnings Potential

When Should You Buy M1 Kliniken AG (ETR:M12)?

Nov 28
When Should You Buy M1 Kliniken AG (ETR:M12)?

Shareholder Returns

M12DE HealthcareDE Market
7D-1.1%0.03%-1.7%
1Y99.4%-5.8%1.4%

Return vs Industry: M12 exceeded the German Healthcare industry which returned -5.8% over the past year.

Return vs Market: M12 exceeded the German Market which returned 1.1% over the past year.

Price Volatility

Is M12's price volatile compared to industry and market?
M12 volatility
M12 Average Weekly Movement7.7%
Healthcare Industry Average Movement5.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market9.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: M12's share price has been volatile over the past 3 months.

Volatility Over Time: M12's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2007366Kilian Brenskewww.m1-kliniken.de

M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, and Australia. The company operates in two segments, Beauty and Trade. It offers aesthetic medical treatments under the M1 Med Beauty brand name across specialist centres; offers surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin, as well as manages a private clinic for plastic and aesthetic surgery under the M1 Schlossklinik brand name.

M1 Kliniken AG Fundamentals Summary

How do M1 Kliniken's earnings and revenue compare to its market cap?
M12 fundamental statistics
Market cap€252.75m
Earnings (TTM)€6.36m
Revenue (TTM)€297.42m

39.8x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
M12 income statement (TTM)
Revenue€297.42m
Cost of Revenue€267.06m
Gross Profit€30.36m
Other Expenses€24.00m
Earnings€6.36m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.35
Gross Margin10.21%
Net Profit Margin2.14%
Debt/Equity Ratio2.4%

How did M12 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.